R Kent McGaughy Jr

CIK 1402856 · last filed 2026-06-12

R Kent McGaughy Jr is a corporate insider who has filed 47 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for TIL, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$65.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.0M across reported positions. 8 SEC filings were submitted jointly with CPMG Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$3.02M

Companies

5

Total Filings

47

Lifetime Open-Market Net

$65.78M

Filer Profile

Reported Address

500 CRESCENT COURT
SUITE 250
DALLAS, MA 75201

Related Filers

CPMG Inc — 8 joint filings, latest 2024-05-07

White Tailed Ptarmigan, LP — 8 joint filings, latest 2024-05-07

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
TIL	Director	410,923	$7.36	$3.02M	$9.00M	8	2026-06-12
REATA PHARMACEUTICALS INC (RETA) Delisted	Director	0	$172.36	$0	$46.76M	29	2023-09-26
Apollo Endosurgery, Inc. (APEN) Delisted	Director	0	$10.00	$0	$10.02M	8	2023-04-04
Apollo Endosurgery, Inc. (LPTN) Delisted	Director	36,608	—	—	$0	1	2016-12-30
GTOP	Director	—	$48.38	—	$0	1	2007-06-13

Recent Filings

47 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-06-12	TIL	Grant (A)	—	$0	EDGAR
2025-05-29	TIL	Grant (A)	—	$0	EDGAR
2024-06-13	TIL	Grant (A)	—	$0	EDGAR
2024-01-10	TIL	Grant (A)	—	$0	EDGAR
2023-09-26	REATA PHARMACEUTICALS INC (RETA) Delisted	Disp (D)	−2,926,776	$0	EDGAR
2023-06-09	REATA PHARMACEUTICALS INC (RETA) Delisted	Grant (A)	—	$0	EDGAR
2023-04-04	Apollo Endosurgery, Inc. (APEN) Delisted	Disp (D)	−6,183,603	$0	EDGAR
2023-03-07	REATA PHARMACEUTICALS INC (RETA) Delisted	Gift (G)	−33,217	$0	EDGAR
2022-12-30	Apollo Endosurgery, Inc. (APEN) Delisted	Conv (C)	+2,198,655	$7.15M	EDGAR
2022-06-16	Apollo Endosurgery, Inc. (APEN) Delisted	Grant (A)	—	$0	EDGAR

Showing 1–10 of 47

Page 1 of 5 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.